The French company Diabeloop SA is now entering the German market as Diabeloop GmbH. Diabeloop developed the self-learning algorithm „DBLG1“, which automates and personalizes the treatment of type 1 diabetes. Therapeutic artificial intelligence is intended to help reduce the psychological burden on diabetics.
Following the pre-launch of DBLG1 in France, the German subsidiary in Siegen is now being prepared for early market entry. Thus, the team around Dr. Christian Key is currently setting up an advisory board in which diabetes experts from research and practice as well as psychologists will exchange ideas. The company is currently in negotiations with statutory and private health insurance companies regarding reimbursement options. In addition, a study program is being considered which, among other things, will conduct studies in Germany and connect German study centers to international studies.
Dr. Andreas Lueg, specialist for internal medicine and diabetology at the L1 Hameln Diabetes Center, assesses the Diabeloop approach as forward-looking. The application contributes to self-determined management of the disease, he says, which allows the patient’s autonomy to be preserved while at the same time reducing psychological pressure in the selection of therapeutic measures. According to Marc Julien, Co-CEO of Diabeloop, patients can lead „a life without interruptions“ thanks to the algorithm.
Quelle: e-health.com